

# Perioperative factor concentrate therapy

K. A. Tanaka<sup>1\*</sup>, S. Esper<sup>1</sup> and D. Bolliger<sup>2</sup>

<sup>1</sup> Department of Anaesthesiology, University of Pittsburgh Medical Center, Pittsburgh, PA, USA

<sup>2</sup> Department of Anaesthesia and Intensive Care Medicine, University Hospital, Basel, Switzerland

\* Corresponding author. E-mail tanakak@upmc.edu

## Editor's key points

- Use of plasma transfusion in perioperative bleeding and coagulopathy is limited by efficacy, volume, preparation, and serious complications.
- Availability of coagulation factor concentrates and point-of-care testing has led to targeted therapy of haemostatic defects.
- Treatment algorithms appear to reduce transfusion of allogeneic blood products through rational use of factor concentrates.

**Summary.** Transfusion of allogeneic plasma has been a life-saving measure for decades in patients with severe trauma or suffering from major surgical blood loss. The safety of allogeneic blood components has improved in terms of pathogen transmission, but haemostatic efficacy of plasma is hindered by the large volume and time required for thawing and infusion. Several plasma-derived and recombinant factor concentrates are clinically available and indicated for targeted replacement of missing coagulation elements in hereditary disorders of thrombosis and haemostasis. When used appropriately, factor concentrate therapy can rapidly restore deficient factor(s) without causing volume overload. The haemostatic defect in perioperative patients is often multifactorial, and therefore careful clinical judgement and timely coagulation testing must be exercised before the administration of factor concentrates. In this review, the rationale for including factor concentrates in perioperative haemostatic management will be discussed in conjunction with the limitations of plasma transfusion.

**Keywords:** antithrombin concentrate; coagulation monitoring; cryoprecipitate; fibrinogen concentrate; fresh-frozen plasma; prothrombin complex concentrate


Haemostasis is a natural defence against vascular injury and haemorrhage.<sup>1</sup> It consists of multiple phases involving both cellular and humoral elements of coagulation (Fig. 1).<sup>2</sup> In the presence of coagulopathy after major trauma and surgery, haemostasis management becomes a major challenge for anaesthesiologists and intensivists.<sup>3–6</sup> The haemostatic defect in perioperative patients is often multifactorial, and coagulation status can deteriorate rapidly. It is thus important to address this problem with comprehensive clinical assessments of coagulopathy, and timely administration of haemostatic therapy.<sup>6–9</sup>

Transfusion of plasma and platelets has been the mainstay of haemostatic therapy for many decades. However, the timing of transfusion is difficult to control, particularly because blood components and laboratory test results are often unavailable in a timely fashion. Delayed decision and administration of transfusion can exacerbate coagulopathy, and potentially affect clinical outcomes. However, premature and overzealous use of haemostatic agents can be equally harmful.<sup>10</sup> For a number of hereditary coagulation factor deficiencies, plasma-derived or recombinant factor concentrates are available to replace the deficient factor(s) without using plasma.<sup>11</sup> The US FDA has recently approved a concentrate of vitamin K-dependent factors for the management of bleeding in patients treated with vitamin K antagonists (e.g. warfarin).<sup>12</sup> When managing perioperative bleeding, these factor concentrates can be more effective than allogeneic plasma, but inappropriate use can be costly and associated

with worsening haemorrhage or thromboembolic complications. This article reviews current limitations of plasma transfusion, current concepts of coagulation monitoring, and the roles of factor concentrates as a perioperative therapy for haemostasis and thrombosis.

## Plasma transfusion

In the case of perioperative bleeding, transfusion of fresh-frozen plasma (FFP; plasma frozen within 8 h) or frozen plasma (FP24; plasma frozen at 8–24 h after collection) is considered a life-saving measure. Thawed FFP and FP24 contain variable, but near-normal, levels of procoagulant proteins, coagulation inhibitors, albumin, and immunoglobulins.<sup>13 14</sup> For example, if fibrinogen is 2 g litre<sup>-1</sup> in a unit of plasma (0.25 litre), it is equivalent to 0.5 g of fibrinogen. However, plasma fibrinogen increases by only 0.4 g litre<sup>-1</sup> after 1 litre of plasma transfusion (median 12.2 ml kg<sup>-1</sup>) in critically ill patients with bleeding or at risk for bleeding.<sup>15</sup> As much as 2.5 litre of plasma transfusion (median 33.5 ml kg<sup>-1</sup>) is required to sufficiently increase fibrinogen by 1 g litre<sup>-1</sup>. This is because the volume of plasma is added to the circulating blood, and as such, fibrinogen is distributed in a larger volume of plasma. Large volumes of plasma transfusion are not tolerated in patients with limited cardiopulmonary reserve, and can be associated with transfusion-associated circulatory overload.<sup>16 17</sup> In addition, transfusion-related acute lung injury (TRALI) is a potentially lethal complication of plasma transfusion, although



the incidence has recently declined from 1:5000 in 2006 to 1:12 000 in 2009 by preferential use of male donor plasma.<sup>18 19</sup>

Variable amounts of immunoglobulins, inflammatory cytokines, and cellular debris are also undesirable contents of allogeneic plasma.<sup>20 21</sup> The volume of plasma transfusion might not be an issue when it is transfused early in the case of massive haemorrhage without excess resuscitative fluids (crystalloids and colloids).<sup>4 22 23</sup> In haemorrhagic shock, plasma transfusion appears to have protective effects on endothelial glycocalyx and syndecan-1, reducing vascular permeability.<sup>24</sup> However, plasma transfusion at a fixed ratio with erythrocytes has not always yielded improved clinical outcomes, indicating some efficacy and safety limitations.<sup>25 26</sup>

The efficacy of plasma transfusion is affected not only by the dose, but also by the timing of intervention. Commonly used laboratory haemostasis assessment includes prothrombin time (PT), activated partial thromboplastin time (aPTT), fibrinogen level (Clauss method), and platelet count. Typical turnaround time (TAT; time from specimen collection to result availability) for these tests is in the range of 30–90 min, which is not optimal in diagnosing coagulopathy or guiding haemostatic

interventions. This is particularly an issue when multiple units of FFP/FP24 must be thawed according to the laboratory data, which adds 30–60 min of processing time. Delays in haemostatic intervention could have serious consequences in the case of bleeding involving vital organs (e.g. cerebral haemorrhage).<sup>27 28</sup>

### Point-of-care coagulation testing

Rapid TAT (<15 min) for PT/INR and fibrinogen level<sup>29</sup> and pre-thawed plasma (type AB or A) have been utilized at major trauma centres in the North America to facilitate timely transfusion,<sup>13</sup> but their availabilities are limited elsewhere.<sup>30</sup> Alternative approaches to conventional laboratory diagnosis and transfusion of haemostatic components (FFP/FP24, platelets, and cryoprecipitate) have emerged in Europe since 2005.<sup>31</sup> The primary approach to perioperative diagnosis of coagulopathy is point-of-care (POC) testing using rotational thromboelastometry (ROTEM®) or thrombelastography (TEG®).<sup>32 33</sup> Viscoelastic properties of clotting in whole blood assessed by ROTEM® and TEG® are highly dependent on thrombin-


mediated fibrin formation and its polymerization. The extent of fibrin polymerization has become an important endpoint in perioperative haemostatic management after FIBTEM became routinely used in ROTEM®.<sup>2, 34–36</sup> As demonstrated in the examples of thromboelastometric tracings (Fig. 2), early amplitudes (A10) or maximum clot firmness (MCF) of EXTEM and FIBTEM can be used for rapid diagnosis (<15–20 min) of dysfunctional fibrin polymerization, and systemic fibrinolysis.<sup>2, 37</sup> Conventional kaolin-TEG® using  $\alpha$ -angle is affected by both platelet count and fibrinogen concentration,<sup>38</sup> and functional fibrinogen assay is considered more specific than TEG®-based detection of hypofibrinogenaemia.<sup>39</sup> On the contrary, fibrin clot firmness cannot be assessed by PT, aPTT, or fibrinogen level, and prolonged PT and aPTT are poor predictors of bleeding and plasma transfusion.<sup>40–42</sup> Large amounts

of plasma transfusion are required to affect clot firmness in ROTEM® and TEG®,<sup>42, 43</sup> and fibrinogen-rich components have recently become the major focus of haemostatic therapy guided by viscoelastic coagulation monitors.<sup>44</sup>

## Fibrinogen-rich components

### Historical aspects

The prototype of cryoprecipitate dates back to 1956 when a product called fraction I-O was extracted by Blombäck<sup>45</sup> from plasma in the presence of glycine in 6.5% ethanol at  $-3^{\circ}\text{C}$ . This fraction was used to treat fibrinogen deficiency, haemophilia A (FVIII deficiency), and an unidentified bleeding disorder at that time [von Willebrand disease (vWD)]. A method to produce cryoprecipitate was developed in 1964 by Pool,



**Fig 2** Examples of rotational thromboelastometric tracings. EXTEM reflects the pattern of whole blood clotting, which is triggered by tissue factor. On the FIBTEM test, fibrin-specific clotting after tissue factor activation is demonstrated by inhibiting platelet–fibrin interactions with cytochalasin D.<sup>2</sup> Normal ranges for EXTEM and FIBTEM are as follows; EXTEM-CT 35–80 s, clot formation time (CFT) 35–160, angle 63–81°, A10 50–71 mm, MCF 53–72 mm; FIBTEM-A10 7–23 mm, MCF 9–25 mm.<sup>33</sup> Pre-treatment: traces obtained from a bleeding patient who incurred major blunt trauma. Prolonged CT and early clot breakdown are notable on EXTEM. Fibrinolysis is corrected *in vitro* on APTM, but CT and amplitude remain abnormal. Severe hypofibrinogenaemia and fibrin breakdown are also observed on FIBTEM. Post-treatment: after treatment with 2 g of tranexamic acid i.v., and transfusion of 20 units cryoprecipitate and 1 units apheresis platelets, CT is nearly normal, and MCF is within normal range on EXTEM. Hyperfibrinolysis is no longer detected (EXTEM = APTM). Fibrin polymerization is improving, but FIBTEM-MCF remains below normal range.

who discovered that slowly thawed FFP leaves behind a cold-insoluble precipitate, which contains fibrinogen, FVIII, von Willebrand factor (vWF), and FXIII.<sup>46 47</sup> High volumes of plasma transfusion in haemophilia A patients were obviated by the use of Pool's cryoprecipitate. Although plasma-derived factor concentrates and recombinant proteins have become the standard for the treatment of haemophilia A and vWD, cryoprecipitate has been the mainstay therapy for fibrinogen replacement in congenital and perioperative fibrinogen deficiency in North America. In European countries where cryoprecipitate is unavailable, plasma-derived fibrinogen concentrate (RiaStap<sup>®</sup>/Haemocomplettan<sup>®</sup>; CSL Behring, Marburg, Germany) has been approved for both congenital and acquired indications.<sup>44 48</sup> In the USA, plasma-derived fibrinogen has been utilized for many years as a key ingredient for topical fibrin sealants,<sup>49</sup> but i.v. injection of fibrinogen concentrate has only recently been approved by the FDA for the treatment of congenital afibrinogenemia or hypofibrinogenemia.<sup>50</sup>

Human plasma-derived fibrinogen concentrate

The characteristics of fibrinogen concentrate, cryoprecipitate, and FFP/FP24 are summarized in Table 1. In contrast to FFP/FP24, fibrinogen concentrate and cryoprecipitate are fractionated (secondary) components of blood, and can be accepted by Jehovah's Witness patients.<sup>51</sup> Fibrinogen concentrate is a lyophilized product, and can be stored at room temperature (<25°C) for up to 30 months.<sup>50</sup> It can be quickly reconstituted and administered intravenously because no thawing or blood type matching is required.<sup>52</sup> In contrast to cryoprecipitate or FFP/FP24, in which fibrinogen content varies, fibrinogen content is standardized in each vial of fibrinogen concentrate (900–1300 mg per vial).<sup>50</sup> Therefore, fibrinogen concentrate (~1000 mg in 50 ml) should be as effective as cryoprecipitate (~300 mg in 20 ml),<sup>53</sup> and superior to FFP/FP24 (~250 mg in

100 ml)<sup>43 47</sup> for fibrinogen replacement. Testing of donor plasma for viral pathogens has reduced the risk of viral transmission with cryoprecipitate and plasma-derived factor concentrate. Pasteurization (60°C for 2 h) and sterile filtrations are applied to fibrinogen concentrate,<sup>54</sup> further reducing the risk of pathogen transmission.<sup>55</sup> The lack of major antibodies in the concentrate reduces the risk of TRALI.

Perioperative hypofibrinogenemia and monitoring fibrinogen level

Hypofibrinogenemia is linked to bleeding by several mechanisms (Fig. 1). In primary haemostasis, fibrinogen is crucial in stabilizing vWF-mediated platelet–platelet interactions, and hypofibrinogenemia results in the formation of small, unstable platelet thrombi.<sup>56 57</sup> In secondary haemostasis, fibrinogen-stabilized platelet thrombi provide a catalytic surface for thrombin generation.<sup>1</sup> Platelet-bound fibrinogen is subsequently converted to fibrin monomer by thrombin, and fibrin monomers are polymerized by thrombin-activated FXIII, a transglutaminase.<sup>44</sup> Paradoxically, hypofibrinogenemia is associated with thromboembolic complications.<sup>58 59</sup> Plausible mechanisms for this include unstable platelet thrombi,<sup>57</sup> reduced sealing of injured vascular wall,<sup>60</sup> and systemic release of thrombin and FXa.<sup>61</sup> Fibrin is historically referred to as ‘antithrombin I’ due to these antithrombotic actions.<sup>58 59</sup>

Target plasma fibrinogen level is usually set at 1 g litre<sup>-1</sup> in congenital fibrinogen deficiency,<sup>62</sup> and similar target levels (0.8–1 g litre<sup>-1</sup>) have been used for acquired deficiency in the perioperative setting.<sup>3</sup> However, higher thresholds (1.5–2 g litre<sup>-1</sup>) have been recommended in recent European transfusion guidelines.<sup>3 63</sup> These changes reflect emerging clinical data supporting early fibrinogen replacement and higher

**Table 1** Characteristics of plasma, cryoprecipitate, and fibrinogen. TRALI, transfusion-related acute lung injury; FFP, fresh-frozen plasma; FP24, plasma frozen within 24 h; IU, international unit of activity. \*Pre-thawed plasma (type AB or A) may be available at major trauma centres in North America. †Pathogen-reduced plasma products are available in North America and European countries

	FFP/FP24 <sup>14</sup>	Cryoprecipitate <sup>47</sup>	Plasma-derived fibrinogen (RiaStap <sup>®</sup> /Haemocomplettan <sup>®</sup> ) <sup>50</sup>
Fibrinogen content per vial or unit	0.5 g	0.3 g	0.9–1.3 g
Volume per vial or unit	250 ml per unit	20 ml per unit	50 ml per vial
Factor concentration	Fibrinogen ~2 g litre <sup>-1</sup> All other factors in variable amounts (0.5–1.5 IU ml <sup>-1</sup> )	Fibrinogen ~15 g litre <sup>-1</sup> Factor XIII 2.8 IU ml <sup>-1</sup> Factor VIII 6.3 IU ml <sup>-1</sup> vWF 8.0 IU ml <sup>-1</sup>	Fibrinogen 20 g litre <sup>-1</sup> Factor XIII 1 IU ml <sup>-1</sup>
Pre-transfusion procedures	Thawing* Blood-type compatibility	Thawing Blood-type compatibility	Mixing with 50 ml diluent Blood-type free
Storage	Frozen	Frozen	Store at room temp. <25°C
Shelf-life	12 months	12 months	30 months
Pathogen reduction	Donor testing†	Donor testing	Precipitation/adsorption, heat-treated for viral inactivation
Other considerations	Immunoglobulins, cytokines, cell debris	Immunoglobulins, cytokines, cell debris	Minimal immunoglobulins (low TRALI risk)

target levels after major trauma, perioperative blood loss, and haemodilution.<sup>34 35 48 64</sup>

Owing to unpredictable TAT of plasma fibrinogen assay, POC assessment of fibrinogen function is preferred in the surgical setting; the ROTEM<sup>®</sup>-based FIBTEM assay is most commonly utilized.<sup>39 65</sup> There are no universally accepted FIBTEM cut-off values for fibrinogen replacement; target fibrinogen levels are different depending on the type and extent of vascular damage (arterial or venous), and levels of other haematological factors (thrombin generation, red blood cell volume, platelet function, etc.).<sup>60</sup> In most adult cardiac surgical patients, a target range of 8–10 mm has been used for FIBTEM-MCF (or A10);<sup>48 66–68</sup> this range roughly corresponds to plasma fibrinogen of 1.5–2 g litre<sup>-1</sup>.<sup>69</sup>

There are some practical considerations for the use of fibrinogen in surgical patients. First, haemostatic efficacy of fibrinogen depends on enzymatic processes, including platelet activation, endogenous thrombin generation, and activated FXIII-mediated polymerization. The use of fibrinogen at early stages of bleeding appears to work well because enzymatic functions are still intact.<sup>34 35 48 64 70</sup> However, fibrinogen replacement *per se* might be insufficient in the case of advanced or late coagulopathy affecting platelets, proenzymes, and the fibrinolytic system.<sup>35 36 48 60 71 72</sup> In contrast to cryoprecipitate, FXIII is not effectively replaced after fibrinogen infusion (Table 1), and separate FXIII infusion is required in some cases.<sup>73</sup> Hyperfibrinolysis cannot be readily diagnosed by plasma fibrinogen level or PT/aPTT.<sup>74</sup> Profibrinolytic state renders fibrinogen replacement ineffective, so it should be monitored by viscoelastic tests, and antifibrinolytic therapy (tranexamic acid or  $\epsilon$ -aminocaproic acid) should be considered (Fig. 2).

### Dosing of fibrinogen concentrate

In bleeding associated with acquired hypofibrinogenaemia in adults, plasma fibrinogen is increased by 0.25–0.28 g litre<sup>-1</sup> (median) per 1 g of fibrinogen administration.<sup>75 76</sup> Gorlinger and colleagues<sup>77</sup> reported that a 25 mg kg<sup>-1</sup> dose of fibrinogen in an 80 kg patient (total 2 g of fibrinogen) results in a 4 mm increase in FIBTEM-MCF (or A10). An average fibrinogen dose of 7.6 mg kg<sup>-1</sup> (0.38 ml kg<sup>-1</sup> vol) is required to increase FIBTEM-MCF by 1 mm in adult cardiac surgical patients with bleeding.<sup>52</sup> In contrast, 11–13 ml kg<sup>-1</sup> of plasma is required to increase FIBTEM-MCF by 1–1.5 mm.

The dose of fibrinogen concentrate is approximated by the following formula:

$$\text{Dose} = \frac{[\text{target FIBTEM-MCF (mm)} - \text{current FIBTEM-MCF (mm)}] \times \text{weight (kg)}}{140}$$

For example, if the FIBTEM-MCF were 6 mm in a 70 kg patient with clinical bleeding, and the target FIBTEM-MCF were 10 mm, the dose of fibrinogen can be calculated to be:

$$\text{Dose} = \frac{(10 - 6) \times 70}{140} = 2 \text{ g}$$

A similar calculation can be also applied to calculate the number of pooled units for cryoprecipitate by using a

factor of 5 (assuming 1 g of fibrinogen in 5 pooled units of cryoprecipitate):

$$\text{Pooled units of cryoprecipitate} = \frac{(10 - 6) \times 70}{140} \times 5 = 10 \text{ U}$$

Titration of the dose of fibrinogen concentrate and cryoprecipitate is important in reducing wastage, and potential thromboembolic complications.

### Contraindications and adverse reactions

Contraindications to fibrinogen concentrate transfusion include a previous history of anaphylactic reaction to the concentrate,<sup>12</sup> and ongoing (or suspected) thrombosis, or myocardial infarction.<sup>78</sup> Adverse reactions associated with fibrinogen concentrate are most commonly fever and headache, but anaphylactic reactions, deep vein thrombosis, pulmonary embolism, and myocardial infarction are potential risks. Thromboembolic complications directly associated with fibrinogen concentrate seem to be infrequent according to post-market surveillance data. Total usage of fibrinogen over 22 yr has amounted to 1 034 389 g, equivalent to 250 000 doses of 4 g fibrinogen. The rate of thrombosis was estimated to be 3.48 events per 10<sup>5</sup> treatments.<sup>79</sup> However, actual incidence of thromboembolic complications could be underreported, and it is often difficult to prove a causal relationship when multiple haemostatic agents are simultaneously administered.

No case of pathogen transmission has been reported for fibrinogen concentrate that undergoes pasteurization (60°C for 2 h) and sterile filtrations.<sup>55</sup>

## Prothrombin complex concentrate

### Historical aspects

Prothrombin complex concentrates (PCCs) are lyophilized, human plasma-derived vitamin K-dependent factors containing FII (prothrombin), FVII, FIX, and FX. PCCs were originally used for FIX replacement in patients with haemophilia B.<sup>80</sup> The potency of PCC is standardized to FIX content [ $\sim$ 500 international unit (IU) per vial]. Lyophilized PCC can be quickly administered in a low volume (typically, 20–100 ml), and is more effective than plasma in restoring FIX activity. However, repeated administration of PCC to maintain FIX activity in haemophilia B patients results in accumulation of prothrombin and FX due to their long half-lives (40–72 h). Excessive thrombin generation might have occurred in haemophilia B patients when FIX was added to a supra-physiological level of prothrombin.<sup>81</sup> Venous thromboembolic events (VTE), pulmonary embolism, and disseminated intravascular coagulation (DIC) have been reported in haemophilia B after repeated doses of PCC since the 1960s.<sup>82</sup> These complications occur far less frequently since the introduction of plasma-derived FIX concentrate, and more recently recombinant FIX for the treatment of haemophilia B.



## PCCs for acute reversal of warfarin

Acute reversal of warfarin using FFP/FP24 is difficult and time-consuming in the case of bleeding complications or emergency surgery.<sup>27–83</sup> Two commercial PCC products are mainly indicated for the reversal of warfarin anticoagulation. Kcentra® (referred to as Beriplex® in Europe; CSL Behring) has been recently approved by the FDA, and Octaplex® (Octapharma, Lachen, Switzerland) is expected to be approved soon. These and other PCCs have been available in Europe and elsewhere for some years.<sup>84</sup> These PCCs contain therapeutic amounts of prothrombin, FVII, FIX, and FX (thus four-factor PCC), and various amounts of protein C, protein S, and protein Z.<sup>81–84–86</sup> Other commercially available PCCs are Bebulin® (Baxter, Westlake Village, CA, USA) and Profilnine® (Grifols, Los Angeles, CA, USA). These are referred to as three-factor PCC, because of low amounts of FVII relative to FII, FIX, and FX (Table 2).

The use of four-factor PCC is preferred for very high INRs (>4–5) when FVII levels are extremely low (<5%).<sup>87–88</sup> Recombinant activated FVII (rFVIIa; NovoSeven®, Novo Nordisk, Bagsbaerd, Denmark) has been used in an attempt to normalize INR in warfarin-treated patients. However, rFVIIa is only effective in shortening PT/INR, and does not restore thrombin generation due to the absence of FII and FX.<sup>89–90</sup> The use of rFVIIa is no longer recommended for warfarin reversal<sup>91</sup> unless it is used (1–2 mg i.v.) in combination with three-factor

PCC.<sup>87–88</sup> Another type of PCC is a haemophilia bypassing agent, factor VIII bypassing agent (FEIBA; Baxter, West Lake Village, CA, USA), which contains prothrombin, FIX, FX, and activated FVII (in addition to traces of thrombin, FIXa, and FXa).<sup>92</sup> FEIBA has also been used for acute warfarin reversal;<sup>93</sup> such use should be cautioned because of underlying thrombophilic issues in warfarin-treated patients (see recent reviews regarding the perioperative implications of rFVIIa<sup>94</sup> and FEIBA<sup>92</sup>). PCCs and FEIBA are considered as a fractionated (secondary) component of blood, and they can be accepted by Jehovah's Witness patients along with recombinant proteins (e.g. erythropoietin, rFVIIa).<sup>51</sup>

PCCs along with FEIBA and rFVIIa have been suggested as a potential reversal agent for novel oral anti-Xa agents (e.g. apixaban, edoxaban, rivaroxaban).<sup>95</sup> However, the supportive data are limited to *in vitro* and animal studies, and *in vivo* haemostatic efficacy of PCCs has not been proven in bleeding patients treated with anti-Xa agents.

## Dosing of PCC

Haemostatic efficacy and pharmacological activity of four-factor PCC compared with FFP have been shown in the multi-centre prospective randomized study of Kcentra® and FFP in warfarin-treated adult patients (INR > 2.0) undergoing urgent surgery or invasive procedures (Table 3).<sup>12</sup> I.V. vitamin K (5–10 mg) was administered to both treatment arms. Clinical haemostasis over 24 h was judged to be effective in 72.4% (71/98) with Kcentra® (median infused volume 90 ml), and 65.4% (68/104) with FFP transfusion (i.e. PCC was non-inferior to FFP).<sup>96</sup> The percentage of cases in which INR was reduced to ≤1.3 after 30 min of intervention was clearly higher with Kcentra® than with FFP: 62.2% (61/98) vs 9.6% (10/104).


Pharmacological data clearly demonstrate the rapid normalization of vitamin K-dependent factors within 30 min using PCC, while it takes a minimum of 3 h for plasma transfusion (and vitamin K) to bring procoagulant levels to ≥50% (Fig. 3).<sup>96</sup> Prothrombin (FII) and FX are replenished to 80–100% activity, and maintained for 24 h by PCC compared with plasma. These proteins have long half-lives (40–72 h), and their hepatic production cannot be acutely increased by vitamin K administration. Plasma levels of FVII and FIX were increased to 60–80% of normal immediately after PCC, but the differences from plasma transfusion became smaller after 12 h due to vitamin K-stimulated endogenous production. Similar findings were found for the anticoagulant proteins, protein C, and protein S (Fig. 3).<sup>96</sup>

**Table 2** Prothrombin complex concentrates. Data indicate relative contents of vitamin K-dependent factors for different PCCs. The per cent (%) activity of each factor is shown relative to FIX activity (based on the prescribing information for each product; actual factor contents may vary for each vial). Manufacturers are as follows: Kcentra®/Beriplex® (CSL Behring, Marburg, Germany), Octaplex® (Octapharma, Lachen, Switzerland), Bebulin® (Baxter, Westlake Village, CA, USA), Profilnine® (Grifols, Los Angeles, CA, USA), and Cofact® (Sanquin, Amsterdam, The Netherlands). Other PCC products are also available in different countries. Protein C/S, protein C/protein S; AT, antithrombin; NR, not reported; Yes, contains therapeutic amounts<sup>11</sup>

Product name	FII	FVII	FIX	FX	Protein C/S	Additive
Kcentra®/Beriplex®	111	57	100	150	Yes	Heparin, AT
Octaplex®	98	66	100	96	Yes	Heparin
Bebulin®	120	13	100	139	NR	Heparin
Profilnine®	148	11	100	64	NR	No heparin
Cofact®	106	48	100	103	Yes	No heparin

**Table 3** Treatments for acute warfarin reversal for the Kcentra® study. This table indicates the study protocol from the Kcentra® study.<sup>96</sup> IU, international unit of factor IX; vit K, vitamin K

INR	PCC treatment (i.v.)	Plasma transfusion (i.v.)
2.0–3.9	PCC 25 IU kg <sup>-1</sup> + vit K 5–10 mg	Plasma 10 ml kg <sup>-1</sup> + vit K 5–10 mg
4.0–5.9	PCC 35 IU kg <sup>-1</sup> + vit K 5–10 mg	Plasma 12 ml kg <sup>-1</sup> + vit K 5–10 mg
≥6.0	PCC 50 IU kg <sup>-1</sup> + vit K 5–10 mg	Plasma 15 ml kg <sup>-1</sup> + vit K 5–10 mg




**Fig 3** Coagulation factor levels in warfarin-treated patients who received four-factor PCC or plasma transfusion. The mean plasma coagulation factor levels [% of normal activity (SD)] for FII (prothrombin), FVII, FIX, FX, protein C (PC), and protein S (PS) are shown over 24 h after the injection of four-factor PCC (4F-PCC) or plasma transfusion.<sup>96</sup> The elapsed time (h) from the treatment is indicated on the horizontal axis. Pre, baseline; F, factor. P-values indicate the significant difference in protein levels between the groups.

The current indication for four-factor PCC is limited to warfarin-related bleeding, but various PCCs have been utilized in acquired, non-warfarin coagulopathy in major trauma and surgical patients (an off-label indication in North America and Europe).<sup>35 36 48 68</sup> The fibrin polymerization defect is the primary target of this haemostatic intervention, and the enzymatic defect is addressed after hypofibrinogenaemia and fibrinolysis (if any) are corrected according to ROTEM<sup>®</sup> assays.<sup>6 35 36 48 68</sup> Prolonged clotting time (CT) on EXTEM over 80–100 s (normal 35–80 s) is used as a cut-off for haemostatic intervention with PCC. Lance and colleagues<sup>97</sup> and Tanaka and colleagues<sup>72</sup> recently demonstrated that prothrombin and FX can be decreased to 30–40% of normal after perioperative haemodilution, and bleeding diathesis can continue after fibrinogen replacement. The rationale for using ROTEM<sup>®</sup>-based assessment in decisions to transfuse PCC, fibrinogen concentrate, or both has been prospectively evaluated by Weber and colleagues<sup>48</sup> compared with centralized laboratory testing in cardiac surgical patients. Four-factor PCC (25 IU kg<sup>-1</sup>) was administered in the presence of prolonged EXTEM-CT (>80 s) and normal fibrin formation, while plasma or PCC was given if INR >1.4 or after 4 units of erythrocytes was transfused (if INR was unavailable) in the cohort evaluated with laboratory tests. The incidence of plasma transfusion was reduced by half (40% vs 80%  $P<0.001$ ) using thromboelastometry guidance. The use of PCC was similar between thromboelastometry and centralized laboratory testing (44% vs 52%  $P=0.433$ ). In the collective data analysis from two prospective randomized studies<sup>48 67</sup> and one case-control study<sup>68</sup> in which factor concentrates were part of a transfusion protocol, transfusions of erythrocytes and plasma were reduced, and the use of PCC and rFVIIa were effectively controlled by thromboelastometry (Fig. 4). The use of ROTEM<sup>®</sup> or TEG<sup>®</sup> generally results in less plasma transfusion with or without factor concentrates.<sup>98</sup>

Although PCC infusion or plasma transfusion guided by ROTEM<sup>®</sup> or TEG<sup>®</sup> is an attractive concept in the management of vitamin K-dependent factor deficiency, there are some precautions. First, the CT of ROTEM<sup>®</sup> and reaction time of TEG<sup>®</sup> do not have the same operating characteristics with PT or aPTT.<sup>7 99–101</sup> PT/INR is more standardized than ROTEM<sup>®</sup> or TEG<sup>®</sup> for warfarin reversal using four-factor PCCs.<sup>85 86</sup> Kaolin-based reaction time (>8 min) by TEG<sup>®</sup> was less predictive of vitamin K-dependent factor deficiency ( $\leq 50\%$  of normal) compared with an INR >1.5 (positive predictive value, 47% and 84%, respectively).<sup>102</sup> Secondly, optimal cut-off values of ROTEM<sup>®</sup>-CT and TEG<sup>®</sup>-reaction time have not been systematically evaluated or standardized.<sup>36 48 68 103 104</sup> Lastly, available haemostatic products vary among different institutions and countries. For example, a timely correction of fibrinogen or vitamin K-dependent factors is difficult when plasma transfusion is the only available source for these factors.

### Contraindications and adverse reactions

Thromboembolic complication is a possible risk of PCCs. In a recent meta-analysis of 27 studies (1032 patients) including both three-factor and four-factor PCCs for the reversal of



**Fig 4** Frequencies of allogeneic blood component transfusion and usage of factor concentrates. Data shown are the percentage of patients who received transfusions of red blood cell (RBC) concentrates, FFP, and platelets in conjunction with fibrinogen concentrate, PCC, or recombinant factor VIIa (rFVIIa) in two randomized controlled studies,<sup>48 67</sup> and in a recent matched case-control trial.<sup>68</sup> Numbers within the columns indicate the number of patients receiving transfusion (or infusion)/total number of patients. Decreased transfusions of RBCs and FFP, and less frequent uses of PCC and rFVIIa were observed in the thromboelastometry-guided group compared with the conventional group (\* $P<0.05$  by  $\chi^2$  test).

vitamin K antagonists, the overall incidence of thromboembolic complications was 1.4% (95% CI, 0.8–2.1).<sup>105</sup> The use of PCCs was rarely the direct cause of death, but total mortality rate was 10.6%, indicating that patients who received PCCs were often very ill. A low risk of thromboembolic events (1:~31 000) was also described in the pharmacovigilance study of Beriplex<sup>®</sup>.<sup>106</sup> The lack of major antibodies in PCCs reduces the risk of TRALI.

The use of PCCs is contraindicated in the case of ongoing DIC.<sup>78</sup> PCCs are known to increase prothrombin and FX levels (half-lives, 40–72 h) in a dose-dependent manner, and the balance of procoagulant and anticoagulant proteins can be shifted towards a hypercoagulable state.

Most PCCs contain subtherapeutic amounts of heparin and antithrombin (AT), although some contain therapeutic amounts of protein C, protein S, and protein Z.<sup>84</sup> Grottke and colleagues<sup>107</sup> reported that a single dose of PCC (50 IU kg<sup>-1</sup>; Cofact, Sanquin, Amsterdam, The Netherlands) was associated with multiple pulmonary microcapillary thrombi and signs of DIC (44%) in a porcine model of haemodilution and hepatic injury. Blood loss was reduced in animals that received the lower dose (35 IU kg<sup>-1</sup>), or in those that did not develop DIC after a dose of 50 IU kg<sup>-1</sup>. In DIC animals, haemostasis was not improved, while plasma AT activity progressively declined to 20%, and thrombin-AT complex levels continued to increase



over 2 h. In PCC-treated animals with improved haemostasis, thrombin generation was well regulated as shown in stable AT activity, and limited increases in thrombin–AT complexes. Taken together, based on this animal study, there could be an increased risk of thromboembolic complications when PCCs are administered in haemodiluted, AT-deficient patients. If AT deficiency is suspected (e.g. liver dysfunction) or known (e.g. hereditary AT deficiency), lower doses of PCCs or AT replacement should be considered, but there is no standardized protocol.

Trace amounts (4–75 units per 10 ml vial) of heparin contained in some PCCs make them contraindicated in patients with heparin-induced thrombocytopenia (HIT), but no such case has been reported to date.<sup>106</sup> Notably, Profilnine, Cofact, FEIBA, and rFVIIa do not contain heparin.

## AT concentrate

### Physiological roles of AT

AT (formerly AT-III) is a 58 kDa glycoprotein that belongs to a family of serine protease inhibitors. AT is synthesized in the

liver, and its plasma half-life is 2.5–3.8 days. The primary targets of AT are serine proteases, thrombin (FIIa), and FXa, which are being constantly generated (i.e. idling state) in the circulation. In asymptomatic patients with hereditary AT deficiency (AT activity, 40–60% of normal), prothrombin fragment 1.2 levels (a marker of thrombin activation by FXa) are twice as high as in those in normal subjects (AT activity, 80–120%). The risk of VTE is inversely proportional to plasma AT activity according to the recent population data from Italy.<sup>108</sup> After adjusting for age, gender, body mass index, and hereditary thrombophilia (6% in patients and 1% in controls), the odds ratio for VTE in individuals with AT activity 45–60% of normal was 7.74-fold higher than for those with AT activity >100%. Similar increases in VTE are also associated with nominal decreases in protein C and protein S activities. These data indicate that both hereditary and acquired deficiencies of natural anticoagulants are important risk modifiers of VTE.

The prevalence of hereditary AT deficiency is estimated to be one in 2000–5000, but acquired deficiency is more frequently diagnosed in clinical practice (Table 4). In cardiovascular patients receiving prolonged heparin infusion (>4–5 days), plasma AT activity decreases progressively to 50–60% of normal. Heparin resistance (or insensitivity) is clinically diagnosed by increased heparin dose requirement, and suboptimal values of aPTT or activated CT (ACT).<sup>109 110</sup> Heparin, low-molecular heparin, and fondaparinux are AT-dependent anticoagulants; therefore, AT deficiency diminishes their antithrombotic efficacies.<sup>111 112</sup>

Currently, plasma-derived AT concentrate (Thrombate III®; Grifols)<sup>113</sup> and recombinant human AT concentrate (ATryn®; rEVO Biologics, Framingham, MA, USA)<sup>114</sup> are commercially available (Table 5). Atenativ (Octapharma, Lachen, Switzerland) and Kybernin (CSL Behring) are plasma-derived AT concentrates available in Europe.<sup>115</sup> Recombinant AT is produced in transgenic goats carrying a human AT gene, and purified from their milk.<sup>116</sup> Both AT concentrates are indicated for prevention of VTE in hereditary AT-deficient patients undergoing surgery and childbirth. Plasma-derived AT concentrate is also indicated for treatment of thromboembolic events in hereditary AT deficiency. For any acquired AT deficiency, it is up to the treating physician to select optimal AT replacement based on clinical

**Table 4** Acquired AT deficiencies

Iatrogenic AT deficiency
Prolonged heparin infusion
L-asparaginase
AT consumption
Surgery/trauma
Extensive cell salvage use
Haemolytic uraemic syndrome
Sepsis/disseminated intravascular coagulation (DIC)
Preeclampsia
Heparin-induced thrombocytopenia
Decreased AT synthesis
Liver dysfunction
Malnutrition
Prematurity/neonates–infants (up to 6 months)
Increased AT excretion
Nephrotic syndrome
Inflammatory bowel disease

**Table 5** Characteristics of AT concentrates. IU, international unit

	Plasma-derived AT <sup>112</sup> (Thrombate III)	Recombinant AT <sup>113</sup> (ATryn)
Half-life	3.8 days (per activity assay) 2.5 days (per immunological assay)	11.6 h (50 IU kg <sup>-1</sup> dose) 17.7 h (100 IU kg <sup>-1</sup> dose)
AT content per vial	500 IU	1750 IU
Heparin content per vial	<0.004 units per IU of AT	<0.0002 units per IU of AT
Storage	Store at room temp <25°C	Store refrigerated at 2–8°C
Shelf-life	3 yr	3 yr
Loading dose (IU)	[(120–baseline AT level) × Wt (kg)]/1.4	Surgical patients: [(120–baseline AT level) × Wt (kg)]/2.3 Peripartum patients: [(120–baseline AT level) × Wt (kg)]/1.3
Maintenance dose	60% of the loading dose repeated (bolus) every 24 h	Surgical patients (IU h <sup>-1</sup> ): [(120–baseline AT level) × Wt (kg)]/10.2 Peripartum patients (IU h <sup>-1</sup> ): [(120–baseline AT level) × Wt (kg)]/5.4 (continuous infusion)

circumstances. Plasma-derived AT is a fractionated (secondary) component of blood, and can be accepted by Jehovah's Witness patients along with recombinant AT.<sup>51</sup> Available clinical data on the management of acquired AT deficiency are discussed below to further our understanding of AT concentrates and other therapeutic options.

### Perioperative heparin resistance and AT replacement

Cardiovascular surgery and extracorporeal circulatory support are two clinical situations where heparin insensitivity is frequently encountered. The definition of heparin resistance is rather arbitrary, and depends on the local practice of heparin dosing, different cut-off values for aPTT or ACT, and availability of other diagnostic testing (e.g. preoperative AT activity).<sup>110</sup> Low AT activity ( $\leq 60\%$ ) is observed in approximately two-thirds of heparin-resistant cases in cardiac surgery, and the remainder is presumably caused by AT-independent mechanisms (e.g. thrombocythaemia).<sup>117–119</sup> Administering more heparin in heparin resistance remains a common practice, and total heparin doses of 800–1200 units  $\text{kg}^{-1}$  have been reported in cardiopulmonary bypass (CPB) procedures.<sup>109</sup> Potential problems associated with large doses of heparin in cardiac surgery include failure to achieve the target ACT, complicated protamine dose calculations, and an increased risk of heparin rebound. As a source of AT, plasma transfusion (typically 2 units) has been empirically given in heparin-resistant cardiac surgical cases.<sup>120</sup> Expected recovery of AT is merely 2–3% per unit of plasma transfusion in an adult, and thus 2 units of FFP/FP24 would minimally affect plasma AT activity after haemodilution during CPB. Indeed, Avidan and colleagues<sup>121</sup> reported that plasma AT activity decreased to 52% on CPB (baseline AT 74%), and ACTs never improved ( $<450$  s) even after 2 units of plasma transfusion. Conversely, AT concentrate products decrease heparin requirement more reliably in heparin-resistant cases. Target ACT values have been achieved in  $\sim 95\%$  of heparin-resistant CPB cases after plasma-derived or recombinant AT products.<sup>118–121</sup> In placebo-controlled studies of recombinant AT ( $75 \text{ IU kg}^{-1}$ ), the intraoperative incidence of plasma transfusion was decreased in the recombinant AT group compared with placebo (19% vs 81%;  $P < 0.001$ ).<sup>121–122</sup>

### Dosing of AT concentrate

The therapeutic dose of AT concentrate can be calculated from the baseline and target plasma levels of AT (Table 5). For example, if baseline AT is 60%, and the target is 80%, the loading dose of plasma-derived AT for a 70 kg adult is calculated as:

$$\text{Dose} = \frac{(80 - 60) \times 70}{1.4} = 1000 \text{ IU}$$

In most heparin-resistant cases, plasma-derived AT is empirically administered as 500–1000 IU (1–2 vials). Expected AT increments of 10–20% are generally sufficient to restore heparin sensitivity in patients with baseline AT activity of 50–60%.<sup>118–123</sup> The initial dose of recombinant AT for peripartum patients is similar to plasma-derived AT, but the lower initial dose is used for surgical patients. Continuous infusion is used

to maintain plasma levels of recombinant AT because its half-life is shorter than that of plasma-derived AT (Table 5). A single bolus dose of  $75 \text{ IU kg}^{-1}$  has been tested in clinical trials of recombinant AT for the management of heparin resistance. The mean AT activity was increased from 78% to 130%, and was maintained at 113% at the end of CPB. Higher AT levels decreased intraoperative heparin and FFP requirements, but caused a trend towards increased 24 h postoperative chest tube drainage. A small increase in postoperative bleeding ( $8 \text{ ml h}^{-1}$ ) was also reported by Ranucci and colleagues<sup>124</sup> in CPB patients who received plasma-derived AT to the target level of 120% before CPB. In their prospective, randomized study, 100 patients received the median AT dose of 1800 IU ( $\sim 22.5 \text{ IU kg}^{-1}$ ), while 100 control patients received none. AT-treated patients had a mean AT activity  $>90\%$  after CPB, and received significantly less heparin and protamine compared with the control group.<sup>124</sup> However, no differences were observed between the groups in the incidence of allogeneic blood component usage, thromboembolic events, low cardiac output, and in-hospital mortality. Taken together, plasma-derived and recombinant AT concentrates are both effective in reducing heparin and/or plasma transfusion in clinical heparin resistance in cardiac surgery. However, the optimal target AT levels in acquired AT deficiency remain elusive, particularly in high-risk cardiac surgical cases with prolonged CPB ( $>2.5$  h).<sup>125</sup> There is a relative paucity of efficacy data of AT replacement in acquired deficiency in liver failure,<sup>126–127</sup> post-trauma,<sup>128</sup> and critical illness.<sup>129</sup> The timing of intervention, co-administration of heparin, and risk–benefit ratio for haemostasis and thrombosis should be carefully considered in these settings.<sup>127–129</sup>

### Contraindications and adverse reactions

Plasma-derived and recombinant AT concentrates have relatively few contraindications and side-effects. Recombinant AT concentrate is contraindicated in patients with hypersensitivity to goat or goat milk proteins.<sup>114</sup> Caution should also be exercised for recombinant AT, as it is used with a different dosing regimen in pregnant patients (Table 5). Bleeding complications (haematoma, haemarthrosis, and haemorrhage, etc.) are rare with either AT concentrate, but such risks might be increased after an unintended overdose, or with anticoagulation (excess heparin). Both AT concentrates contain a miniscule amount of heparin, but no association of AT concentrates with HIT has been reported to date. Heat treatment and sterile filtration are applied to plasma-derived and recombinant AT concentrates, minimizing the risk of pathogen transmission.<sup>113–114</sup>

### Conclusion

Plasma transfusion has been the mainstay haemostatic intervention for decades for the prevention and treatment of haemorrhagic and prothrombotic conditions, often without clearly defined therapeutic goals.<sup>40–41</sup> Its low therapeutic efficacy, time limitations for thawing and infusion, and potential hazards have been increasingly recognized, particularly in perioperative and critically ill patients.<sup>17</sup> Biotherapeutic and pharmacological factor concentrates have been used for the

past half-century for treatment of hereditary haematological disorders.<sup>80</sup> Mechanisms of action and safety profiles of these concentrates have been largely defined within the labelled indications through clinical studies, registries, and post-marketing surveillance.<sup>79 105 106</sup> Perioperative use of most factor concentrates is still regarded as non-routine and difficult because multifactorial coagulopathy cannot be diagnosed by standard coagulation tests in a timely fashion, and plasma transfusion is often empirically administered.<sup>9</sup> Early replacement of fibrinogen and correction of hyperfibrinolysis have become widely utilized in Europe after rapid diagnosis of hypofibrinogenaemia and/or fibrinolysis became feasible using thromboelastometry.<sup>3 63 130</sup> The implementation of haemostasis algorithms guided by thromboelastometry appears to reduce allogeneic blood product usage, and leads to rational use of factor concentrates.<sup>48 63</sup> The use of factor concentrates is not intended to eradicate plasma transfusion, which has become increasingly safer.<sup>18 19 131</sup> Preferably, factor concentrates should be included in patient blood management to reduce unnecessary plasma and erythrocyte transfusion.<sup>132 133</sup> The recent FDA approval of a four-factor PCC will change management of acute warfarin reversal, and reduce the need for plasma transfusion in the perioperative period.<sup>12</sup> In many countries, most perioperative uses of PCC, fibrinogen, and AT concentrates are currently considered as 'off-label', but accumulating clinical data indicate that they have important roles in the management of perioperative haemorrhage, and prevention of thrombosis.<sup>110 131</sup>

In contrast to hereditary conditions where a single concentrate is indicated, perioperative coagulopathy often requires multiple haemostatic agents in conjunction with allogeneic blood components.<sup>48 51 72 97</sup> Cumulative clinical data in Europe demonstrate that a combination therapy of factor concentrates and allogeneic blood components is feasible and more efficient using transfusion algorithms based on POC coagulation tests compared with conventional laboratory methods.<sup>48 63</sup> Additional efficacy and safety data are needed to establish proper perioperative indications, target levels for specific factor replacement, and cost implications in diverse perioperative populations (e.g. military casualty, geriatric, and paediatric patients). Ongoing clinical studies on allogeneic components,<sup>134</sup> factor concentrates,<sup>135</sup> and synthetic agents<sup>136 137</sup> will clarify optimal transfusion algorithms and strategies to re-establish the balance of coagulation.<sup>136 137</sup>

## Authors' contributions

K.A.T. has put forth the overall concept of this review article. S.E. and D.B. have contributed clinical information, and helped with the manuscript preparation.

## Declaration of interest

K.A.T. has served as a consultant for TEM International (Munich, Germany), Grifols (Research Triangle Park, NC, USA), and Octapharma (Hoboken, NJ, USA), and previously received research support from CSL Behring (Marburg, Germany); D.B. received honoraria for lecturing from TEM International, and

a non-restricted research grant from CSL Behring (Berne, Switzerland). None of the companies were involved in the manuscript preparation.

## Funding

None declared.

## References

- 1 Tanaka KA, Key NS, Levy JH. Blood coagulation: hemostasis and thrombin regulation. *Anesth Analg* 2009; **108**: 1433–46
- 2 Tanaka KA, Bolliger D, Vadlamudi R, Nimmo A. Rotational thromboelastometry (ROTEM)-based coagulation management in cardiac surgery and major trauma. *J Cardiothorac Vasc Anesth* 2012; **26**: 1083–93
- 3 Bolliger D, Gorlinger K, Tanaka KA. Pathophysiology and treatment of coagulopathy in massive hemorrhage and hemodilution. *Anesthesiology* 2010; **113**: 1205–19
- 4 Dutton RP. Haemostatic resuscitation. *Br J Anaesth* 2012; **109** (Suppl. 1): i39–46
- 5 Schochl H, Grassetto A, Schlomp CJ. Management of hemorrhage in trauma. *J Cardiothorac Vasc Anesth* 2013; **27**: S35–43
- 6 Gorlinger K, Shore-Lesserson L, Dirkmann D, Hanke A, Rahe-Meyer N, Tanaka KA. Management of hemorrhage in cardiothoracic surgery. *J Cardiothorac Vasc Anesth* 2013; **27**: S20–34
- 7 Nuttall GA, Oliver WC, Ereth MH, Santrach PJ. Coagulation tests predict bleeding after cardiopulmonary bypass. *J Cardiothorac Vasc Anesth* 1997; **11**: 815–23
- 8 Nuttall GA. Goal-directed therapy: evidence and outcome. *J Cardiothorac Vasc Anesth* 2013; **27**: S6–8
- 9 Tanaka KA, Bader SO, Sturgill EL. Diagnosis of perioperative coagulopathy—plasma versus whole blood testing. *J Cardiothorac Vasc Anesth* 2013; **27**: S9–15
- 10 Hannon T. Trauma blood management: avoiding the collateral damage of trauma resuscitation protocols. *Hematology Am Soc Hematol Educ Program* 2010; **1**: 463–4
- 11 Brooker M. *Registry of Clotting Factor Concentrate*, 9th edn. Montreal: World Federation of Hemophilia, 2012
- 12 Kcentra, Prothrombin Complex Concentrate (Human). *Prescribing Information*. Marburg, Germany: CSL Behring, April 2013
- 13 Downes KA, Wilson E, Yomtovian R, Sarode R. Serial measurement of clotting factors in thawed plasma stored for 5 days. *Transfusion* 2001; **41**: 570
- 14 Theusinger OM, Baulig W, Seifert B, Emmert MY, Spahn DR, Asmis LM. Relative concentrations of haemostatic factors and cytokines in solvent/detergent-treated and fresh-frozen plasma. *Br J Anaesth* 2011; **106**: 505–11
- 15 Chowdary P, Saayman AG, Paulus U, Findlay GP, Collins PW. Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. *Br J Haematol* 2004; **125**: 69–73
- 16 Narick C, Triulzi DJ, Yazer MH. Transfusion-associated circulatory overload after plasma transfusion. *Transfusion* 2012; **52**: 160–5
- 17 Kor DJ, Stubbs JR, Gajic O. Perioperative coagulation management—fresh frozen plasma. *Best Pract Res Clin Anaesthesiol* 2010; **24**: 51–64
- 18 Chapman CE, Stainsby D, Jones H, et al. Ten years of hemovigilance reports of transfusion-related acute lung injury in the United Kingdom and the impact of preferential use of male donor plasma. *Transfusion* 2009; **49**: 440–52



- 19 Toy P, Gajic O, Bacchetti P, et al. Transfusion-related acute lung injury: incidence and risk factors. *Blood* 2012; **119**: 1757–67
- 20 Nielsen HJ, Reimert C, Pedersen AN, et al. Leucocyte-derived bioactive substances in fresh frozen plasma. *Br J Anaesth* 1997; **78**: 548–52
- 21 Schneider SO, Rensing H, Graber S, et al. Impact of platelets and fresh frozen plasma in contrast to red cell concentrate on unstimulated and stimulated cytokine release in an in vitro model of transfusion. *Scand J Immunol* 2009; **70**: 101–5
- 22 Holcomb JB, Wade CE, Michalek JE, et al. Increased plasma and platelet to red blood cell ratios improves outcome in 466 massively transfused civilian trauma patients. *Ann Surg* 2008; **248**: 447–58
- 23 Bolliger D, Szlam F, Levy JH, Molinaro RJ, Tanaka KA. Haemodilution-induced profibrinolytic state is mitigated by fresh-frozen plasma: implications for early haemostatic intervention in massive haemorrhage. *Br J Anaesth* 2010; **104**: 318–25
- 24 Kozar RA, Peng Z, Zhang R, et al. Plasma restoration of endothelial glycocalyx in a rodent model of hemorrhagic shock. *Anesth Analg* 2011; **112**: 1289–95
- 25 Watson GA, Sperry JL, Rosengart MR, et al. Fresh frozen plasma is independently associated with a higher risk of multiple organ failure and acute respiratory distress syndrome. *J Trauma* 2009; **67**: 221–7
- 26 Ho AM, Dion PW, Yeung JH, et al. Prevalence of survivor bias in observational studies on fresh frozen plasma: erythrocyte ratios in trauma requiring massive transfusion. *Anesthesiology* 2012; **116**: 716–28
- 27 Goldstein JN, Thomas SH, Frontiero V, et al. Timing of fresh frozen plasma administration and rapid correction of coagulopathy in warfarin-related intracerebral hemorrhage. *Stroke* 2006; **37**: 151–5
- 28 Mayer SA, Rincon F. Ultra-early hemostatic therapy for acute intracerebral hemorrhage. *Semin Hematol* 2006; **43**: S70–6
- 29 Chandler WL, Ferrell C, Trimble S, Moody S. Development of a rapid emergency hemorrhage panel. *Transfusion* 2010; **50**: 2547–52
- 30 Mehr CR, Gupta R, von Recklinghausen FM, Szczepiorkowski ZM, Dunbar NM. Balancing risk and benefit: maintenance of a thawed Group A plasma inventory for trauma patients requiring massive transfusion. *J Trauma Acute Care Surg* 2013; **74**: 1425–31
- 31 Heindl B, Delorenzo C, Spannagl M. High dose fibrinogen administration for acute therapy of coagulopathy during massive perioperative transfusion. *Anaesthesist* 2005; **54**: 787–90
- 32 Ganter MT, Hofer CK. Coagulation monitoring: current techniques and clinical use of viscoelastic point-of-care coagulation devices. *Anesth Analg* 2008; **106**: 1366–75
- 33 Bolliger D, Seeberger MD, Tanaka KA. Principles and practice of thromboelastography in clinical coagulation management and transfusion practice. *Transfus Med Rev* 2012; **26**: 1–13
- 34 Fenger-Eriksen C, Jensen TM, Kristensen BS, et al. Fibrinogen substitution improves whole blood clot firmness after dilution with hydroxyethyl starch in bleeding patients undergoing radical cystectomy: a randomized, placebo-controlled clinical trial. *J Thromb Haemost* 2009; **7**: 795–802
- 35 Schochl H, Nienaber U, Hofer G, et al. Goal-directed coagulation management of major trauma patients using thromboelastometry (ROTEM)-guided administration of fibrinogen concentrate and prothrombin complex concentrate. *Crit Care* 2010; **14**: R55
- 36 Gorlinger K, Dirkmann D, Hanke AA, et al. First-line therapy with coagulation factor concentrates combined with point-of-care coagulation testing is associated with decreased allogeneic blood transfusion in cardiovascular surgery: a retrospective, single-center cohort study. *Anesthesiology* 2011; **115**: 1179–91
- 37 Gorlinger K, Dirkmann D, Solomon C, Hanke AA. Fast interpretation of thromboelastometry in non-cardiac surgery: reliability in patients with hypo-, normo-, and hypercoagulability. *Br J Anaesth* 2013; **110**: 222–30
- 38 Larsen OH, Fenger-Eriksen C, Christiansen K, Ingerslev J, Sorensen B. Diagnostic performance and therapeutic consequence of thromboelastometry activated by kaolin versus a panel of specific reagents. *Anesthesiology* 2011; **115**: 294–302
- 39 Solomon C, Sorensen B, Hochleitner G, Kashuk J, Ranucci M, Schochl H. Comparison of whole blood fibrin-based clot tests in thrombelastography and thromboelastometry. *Anesth Analg* 2012; **114**: 721–30
- 40 Dzik WH. Predicting hemorrhage using preoperative coagulation screening assays. *Curr Hematol Rep* 2004; **3**: 324–30
- 41 Stanworth SJ. The evidence-based use of FFP and cryoprecipitate for abnormalities of coagulation tests and clinical coagulopathy. *Hematology Am Soc Hematol Educ Program* 2007: 179–86
- 42 Holcomb JB, Minei KM, Scerbo ML, et al. Admission rapid thrombelastography can replace conventional coagulation tests in the emergency department: experience with 1974 consecutive trauma patients. *Ann Surg* 2012; **256**: 476–86
- 43 Rumph B, Bolliger D, Narang N, et al. In vitro comparative study of hemostatic components in warfarin-treated and fibrinogen-deficient plasma. *J Cardiothorac Vasc Anesth* 2010; **24**: 408–12
- 44 Levy JH, Szlam F, Tanaka KA, Sniecinski RM. Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. *Anesth Analg* 2012; **114**: 261–74
- 45 Blomback B. Travels with fibrinogen. *J Thromb Haemost* 2006; **4**: 1653–60
- 46 Kasper CK. Judith Graham Pool and the discovery of cryoprecipitate. *Haemophilia* 2012; **18**: 833–5
- 47 Caudill JS, Nichols WL, Plumphoff EA, et al. Comparison of coagulation factor XIII content and concentration in cryoprecipitate and fresh-frozen plasma. *Transfusion* 2009; **49**: 765–70
- 48 Weber CF, Gorlinger K, Meininger D, et al. Point-of-care testing: a prospective, randomized clinical trial of efficacy in coagulopathic cardiac surgery patients. *Anesthesiology* 2012; **117**: 531–47
- 49 Achneck HE, Sileshi B, Jamiolkowski RM, Albala DM, Shapiro ML, Lawson JH. A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. *Ann Surg* 2010; **251**: 217–28
- 50 RiaSTAP, Fibrinogen Concentrate (Human). *Prescribing Information*. CSL Behring: Marburg, Germany, December 2011
- 51 Bolliger D, Sreeram G, Duncan A, et al. Prophylactic use of factor IX concentrate in a Jehovah's Witness patient. *Ann Thorac Surg* 2009; **88**: 1666–8
- 52 Solomon C, Pichlmaier U, Schoechl H, et al. Recovery of fibrinogen after administration of fibrinogen concentrate to patients with severe bleeding after cardiopulmonary bypass surgery. *Br J Anaesth* 2010; **104**: 555–62
- 53 Theodoulou A, Berryman J, Nathwani A, Scully M. Comparison of cryoprecipitate with fibrinogen concentrate for acquired hypofibrinogenemia. *Transfus Apher Sci* 2012; **46**: 159–62
- 54 Sorensen B, Bevan D. A critical evaluation of cryoprecipitate for replacement of fibrinogen. *Br J Haematol* 2010; **149**: 834–43
- 55 Groner A. Reply: Pereira A. Cryoprecipitate versus commercial fibrinogen concentrate in patients who occasionally require a therapeutic supply of fibrinogen: risk comparison in the case of an emerging transfusion-transmitted infection. *Haematologica* 2008; **93**: e24–6; author reply e27
- 56 Ruggeri ZM. Mechanisms initiating platelet thrombus formation. *Thromb Haemost* 1997; **78**: 611–6

- 57 Ni H, Denis CV, Subbarao S, et al. Persistence of platelet thrombus formation in arterioles of mice lacking both von Willebrand factor and fibrinogen. *J Clin Invest* 2000; **106**: 385–92
- 58 Mosesson MW. Update on antithrombin I (fibrin). *Thromb Haemost* 2007; **98**: 105–8
- 59 Ariens RA. Fibrin(ogen) and thrombotic disease. *J Thromb Haemost* 2013; **11** (Suppl. 1): 294–305
- 60 Ogawa S, Ohnishi T, Hosokawa K, Szlam F, Chen EP, Tanaka KA. Haemodilution-induced changes in coagulation and effects of haemostatic components under flow conditions. *Br J Anaesth* 2013 Advance Access published on 20 June 2013, doi:10.1093/bja/aet229
- 61 Hathcock JJ, Nemerson Y. Platelet deposition inhibits tissue factor activity: in vitro clots are impermeable to factor Xa. *Blood* 2004; **104**: 123–7
- 62 Bornikova L, Peyvandi F, Allen G, Bernstein J, Manco-Johnson MJ. Fibrinogen replacement therapy for congenital fibrinogen deficiency. *J Thromb Haemost* 2011; **9**: 1687–704
- 63 Kozek-Langenecker SA, Afshari A, Albaladejo P, et al. Management of severe perioperative bleeding: guidelines from the European Society of Anaesthesiology. *Eur J Anaesthesiol* 2013; **30**: 270–382
- 64 Rahe-Meyer N, Solomon C, Hanke A, et al. Effects of fibrinogen concentrate as first-line therapy during major aortic replacement surgery: a randomized, placebo-controlled trial. *Anesthesiology* 2013; **118**: 40–50
- 65 Solomon C, Cadamuro J, Ziegler B, et al. A comparison of fibrinogen measurement methods with fibrin clot elasticity assessed by thromboelastometry, before and after administration of fibrinogen concentrate in cardiac surgery patients. *Transfusion* 2011; **51**: 1695–706
- 66 Haas T, Fries D, Velik-Salchner C, Oswald E, Innerhofer P. Fibrinogen in craniostomosis surgery. *Anesth Analg* 2008; **106**: 725–31, table of contents
- 67 Girdauskas E, Kempfert J, Kuntze T, et al. Thromboelastometrically guided transfusion protocol during aortic surgery with circulatory arrest: a prospective, randomized trial. *J Thorac Cardiovasc Surg* 2010; **140**: 1117–24 e2
- 68 Fassl J, Matt P, Eckstein F, et al. Transfusion of allogeneic blood products in proximal aortic surgery with hypothermic circulatory arrest: effects of thromboelastometry-guided transfusion management. *J Cardiothorac Vasc Anesth* 2013, doi:10.1053/j.jvca.2013.02.009 (e-pub ahead of print)
- 69 Ogawa S, Szlam F, Bolliger D, Nishimura T, Chen EP, Tanaka KA. The impact of hematocrit on fibrin clot formation assessed by rotational thromboelastometry. *Anesth Analg* 2012; **115**: 16–21
- 70 Hiippala ST, Myllylä GJ, Vahtera EM. Hemostatic factors and replacement of major blood loss with plasma-poor red cell concentrates. *Anesth Analg* 1995; **81**: 360–5
- 71 Bilecen S, Peelen LM, Kalkman CJ, Spanjersberg AJ, Moons KG, Nierich AP. Fibrinogen concentrate therapy in complex cardiac surgery. *J Cardiothorac Vasc Anesth* 2013; **27**: 12–7
- 72 Tanaka KA, Egan K, Szlam F, et al. Transfusion and hematologic variables after fibrinogen or platelet transfusion in valve replacement surgery: preliminary data of purified lyophilized human fibrinogen concentrate versus conventional transfusion. *Transfusion* 2013, doi:10.1111/trf.12248 (e-pub ahead of print)
- 73 Korte WC, Szadkowski C, Gahler A, et al. Factor XIII substitution in surgical cancer patients at high risk for intraoperative bleeding. *Anesthesiology* 2009; **110**: 239–45
- 74 Schochl H, Frietsch T, Pavelka M, Jambor C. Hyperfibrinolysis after major trauma: differential diagnosis of lysis patterns and prognostic value of thrombelastometry. *J Trauma* 2009; **67**: 125–31
- 75 Danes AF, Cuenca LG, Bueno SR, Mendarte Barrenechea L, Ronsano JB. Efficacy and tolerability of human fibrinogen concentrate administration to patients with acquired fibrinogen deficiency and active or in high-risk severe bleeding. *Vox Sang* 2008; **94**: 221–6
- 76 Weinkove R, Rangarajan S. Fibrinogen concentrate for acquired hypofibrinogenaemic states. *Transfus Med* 2008; **18**: 151–7
- 77 Gorlinger K, Fries D, Dirkmann D, Weber CF, Hanke AA, Schochl H. Reduction of fresh frozen plasma requirements by perioperative point-of-care coagulation management with early calculated goal-directed therapy. *Transfus Med Hemother* 2012; **39**: 104–13
- 78 Santhosh J. Cross-sectional guidelines for therapy with blood components and plasma derivatives: Chapter 7 Procoagulants. *Transfus Med Hemother* 2009; **36**: 419–36
- 79 Dickneite G, Pragst I, Joch C, Bergman GE. Animal model and clinical evidence indicating low thrombogenic potential of fibrinogen concentrate (Haemocomplettan P). *Blood Coagul Fibrinolysis* 2009; **20**: 535–40
- 80 Key NS, Negrier C. Coagulation factor concentrates: past, present, and future. *Lancet* 2007; **370**: 439–48
- 81 Sorensen B, Spahn DR, Innerhofer P, Spannagl M, Rossaint R. Clinical review: prothrombin complex concentrates—evaluation of safety and thrombogenicity. *Crit Care* 2011; **15**: 201
- 82 Lusher JM. Thrombogenicity associated with factor IX complex concentrates. *Semin Hematol* 1991; **28**: 3–5
- 83 Ageno W, Gallus AS, Wittkowsky A, Crowther M, Hylek EM, Palareti G. Oral anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**: e44–88S
- 84 Levy JH, Tanaka KA, Dietrich W. Perioperative hemostatic management of patients treated with vitamin K antagonists. *Anesthesiology* 2008; **109**: 918–26
- 85 Riess HB, Meier-Hellmann A, Motsch J, Elias M, Kursten FW, Dempfle CE. Prothrombin complex concentrate (Octaplex) in patients requiring immediate reversal of oral anticoagulation. *Thromb Res* 2007; **121**: 9–16
- 86 Pabinger I, Brenner B, Kalina U, Knaub S, Nagy A, Ostermann H. Prothrombin complex concentrate (Beriplex P/N) for emergency anticoagulation reversal: a prospective multinational clinical trial. *J Thromb Haemost* 2008; **6**: 622–31
- 87 Sarode R, Rawal A, Lee R, Shen YM, Frenkel EP. Poor correlation of supratherapeutic international normalized ratio and vitamin K-dependent procoagulant factor levels during warfarin therapy. *Br J Haematol* 2005; **132**: 604–7
- 88 Holland L, Warkentin TE, Refaai M, Crowther MA, Johnston MA, Sarode R. Suboptimal effect of a three-factor prothrombin complex concentrate (Profilnine-SD) in correcting supratherapeutic international normalized ratio due to warfarin overdose. *Transfusion* 2009; **49**: 1171–7
- 89 Tanaka KA, Szlam F, Dickneite G, Levy JH. Effects of prothrombin complex concentrate and recombinant activated factor VII on vitamin K antagonist induced anticoagulation. *Thromb Res* 2008; **122**: 117–23
- 90 Skolnick BE, Mathews DR, Khutoryansky NM, Pusateri AE, Carr ME. Exploratory study on the reversal of warfarin with rFVIIa in healthy subjects. *Blood* 2010; **116**: 693–701
- 91 Holbrook A, Schulman S, Witt DM, et al. Evidence-based management of anticoagulant therapy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. *Chest* 2012; **141**: e152–84S.



- 92 Hoffman M, Dargaud Y. Mechanisms and monitoring of bypassing agent therapy. *J Thromb Haemost* 2012; **10**: 1478–85
- 93 Wojcik C, Schymik ML, Cure EG. Activated prothrombin complex concentrate factor VIII inhibitor bypassing activity (FEIBA) for the reversal of warfarin-induced coagulopathy. *Int J Emerg Med* 2009; **2**: 217–25
- 94 Levi M, Levy JH, Andersen HF, Truloff D. Safety of recombinant activated factor VII in randomized clinical trials. *N Engl J Med* 2010; **363**: 1791–800
- 95 Tanaka KA, Bolliger D. On the reversal of new oral anti-coagulants: can we simply extrapolate data from the animal models to humans? *Br J Anaesth* 2013; **110**: 329–32
- 96 Sarode R, Milling TJ Jr., Refaai MA, et al. Efficacy and safety of a four-factor prothrombin complex concentrate (4F-PCC) in patients on vitamin K antagonists presenting with major bleeding: a randomized, plasma-controlled, phase IIIb study. *Circulation* 2013, doi:10.1161/CIRCULATIONAHA.113.002283 (e-pub ahead of print)
- 97 Lance MD, Ninivaggi M, Schols SE, et al. Perioperative dilutional coagulopathy treated with fresh frozen plasma and fibrinogen concentrate: a prospective randomized intervention trial. *Vox Sang* 2012; **103**: 25–34
- 98 Bolliger D, Tanaka A. Roles of thrombelastography and thromboelastometry for the patient blood management in cardiac surgery. *Transfus Med Rev* 2013, doi:10.1016/j.tmr.2013.08.004 (e-pub ahead of print)
- 99 Gorlinger K. Coagulation management during liver transplantation. *Hamostaseologie* 2006; **26**: S64–76
- 100 Rugeri L, Levrat A, David JS, et al. Diagnosis of early coagulation abnormalities in trauma patients by rotation thrombelastography. *J Thromb Haemost* 2007; **5**: 289–95
- 101 Ogawa S, Szlam F, Chen EP, et al. A comparative evaluation of rotation thromboelastometry and standard coagulation tests in hemodilution-induced coagulation changes after cardiac surgery. *Transfusion* 2012; **52**: 14–22
- 102 Nascimento B, Al Mahoos M, Callum J, et al. Vitamin K-dependent coagulation factor deficiency in trauma: a comparative analysis between international normalized ratio and thromboelastography. *Transfusion* 2012; **52**: 7–13
- 103 Shore-Lesserson L, Manspeizer HE, DePerio M, Francis S, Vela-Cantos F, Ergin MA. Thromboelastography-guided transfusion algorithm reduces transfusions in complex cardiac surgery. *Anesth Analg* 1999; **88**: 312–9
- 104 Johansson PI, Stensballe J. Effect of haemostatic control resuscitation on mortality in massively bleeding patients: a before and after study. *Vox Sang* 2009; **96**: 111–8
- 105 Majeed A, Eelde A, Agren A, Schulman S, Holmstrom M. Thromboembolic safety and efficacy of prothrombin complex concentrates in the emergency reversal of warfarin coagulopathy. *Thromb Res* 2012; **129**: 146–51
- 106 Hanke AA, Joch C, Gorlinger K. Long-term safety and efficacy of a pasteurized nanofiltrated prothrombin complex concentrate (Beriplex P/N): a pharmacovigilance study. *Br J Anaesth* 2013; **110**: 764–72
- 107 Grottko O, Braunschweig T, Spronk HM, et al. Increasing concentrations of prothrombin complex concentrate induce disseminated intravascular coagulation in a pig model of coagulopathy with blunt liver injury. *Blood* 2011; **118**: 1943–51
- 108 Bucciarelli P, Passamonti SM, Biguzzi E, et al. Low borderline plasma levels of antithrombin, protein C and protein S are risk factors for venous thromboembolism. *J Thromb Haemost* 2012; **10**: 1783–91
- 109 Spiess BD. Treating heparin resistance with antithrombin or fresh frozen plasma. *Ann Thorac Surg* 2008; **85**: 2153–60
- 110 Finley A, Greenberg C. Review article: heparin sensitivity and resistance: management during cardiopulmonary bypass. *Anesth Analg* 2013; **116**: 1210–22
- 111 Lehman CM, Rettmann JA, Wilson LW, Markewitz BA. Comparative performance of three anti-factor Xa heparin assays in patients in a medical intensive care unit receiving intravenous, unfractionated heparin. *Am J Clin Pathol* 2006; **126**: 416–21
- 112 Fukuda T, Kamisato C, Honda Y, et al. Impact of antithrombin deficiency on efficacy of edoxaban and antithrombin-dependent anticoagulants, fondaparinux, enoxaparin, and heparin. *Thromb Res* 2013; **131**: 540–6
- 113 Thrombate III, Antithrombin III (Human). *Prescribing Information*. Research Triangle Park, NC: Grifols Therapeutics, October 2012
- 114 ATryn, Antithrombin (Recombinant). *Prescribing Information*. Framingham, MA: GTC Biotherapeutics, November 2010
- 115 Rodgers GM. Role of antithrombin concentrate in treatment of hereditary antithrombin deficiency. An update. *Thromb Haemost* 2009; **101**: 806–12
- 116 Levy JH, Weisinger A, Ziomek CA, Echelard Y. Recombinant antithrombin: production and role in cardiovascular disorder. *Semin Thromb Hemost* 2001; **27**: 405–16
- 117 Ranucci M, Isgro G, Cazzaniga A, Soro G, Menicanti L, Frigiola A. Predictors for heparin resistance in patients undergoing coronary artery bypass grafting. *Perfusion* 1999; **14**: 437–42
- 118 Williams MR, D'Ambra AB, Beck JR, et al. A randomized trial of antithrombin concentrate for treatment of heparin resistance. *Ann Thorac Surg* 2000; **70**: 873–7
- 119 Ranucci M, Isgro G, Cazzaniga A, et al. Different patterns of heparin resistance: therapeutic implications. *Perfusion* 2002; **17**: 199–204
- 120 Sabbagh AH, Chung GK, Shuttleworth P, Applegate BJ, Gabrhe W. Fresh frozen plasma: a solution to heparin resistance during cardiopulmonary bypass. *Ann Thorac Surg* 1984; **37**: 466–8
- 121 Avidan MS, Levy JH, Scholz J, et al. A phase III, double-blind, placebo-controlled, multicenter study on the efficacy of recombinant human antithrombin in heparin-resistant patients scheduled to undergo cardiac surgery necessitating cardiopulmonary bypass. *Anesthesiology* 2005; **102**: 276–84
- 122 Avidan MS, Levy JH, van Aken H, et al. Recombinant human antithrombin III restores heparin responsiveness and decreases activation of coagulation in heparin-resistant patients during cardiopulmonary bypass. *J Thorac Cardiovasc Surg* 2005; **130**: 107–13
- 123 Levy JH, Montes F, Szlam F, Hillyer CD. The in vitro effects of antithrombin III on the activated coagulation time in patients on heparin therapy. *Anesth Analg* 2000; **90**: 1076–9
- 124 Ranucci M, Baryshnikova E, Crapelli GB, Woodward MK, Paez A, Pelissero G. Preoperative antithrombin supplementation in cardiac surgery: a randomized controlled trial. *J Thorac Cardiovasc Surg* 2013; **145**: 1393–9
- 125 Ogawa S, Richardson JE, Sakai T, Ide M, Tanaka KA. High mortality associated with intracardiac and intrapulmonary thromboses after cardiopulmonary bypass. *J Anesth* 2012; **26**: 9–19
- 126 Langley PG, Hughes RD, Forbes A, Keays R, Williams R. Controlled trial of antithrombin III supplementation in fulminant hepatic failure. *J Hepatol* 1993; **17**: 326–31
- 127 Kawanaka H, Akahoshi T, Kinjo N, et al. Impact of antithrombin III concentrates on portal vein thrombosis after splenectomy in patients with liver cirrhosis and hypersplenism. *Ann Surg* 2010; **251**: 76–83

- 128 Waydhas C, Nast-Kolb D, Gippner-Steppert C, et al. High-dose antithrombin III treatment of severely injured patients: results of a prospective study. *J Trauma* 1998; **45**: 931–40
- 129 Warren BL, Eid A, Singer P, et al. Caring for the critically ill patient. High-dose antithrombin III in severe sepsis: a randomized controlled trial. *J Am Med Assoc* 2001; **286**: 1869–78
- 130 Gorlinger K, Dirkmann D, Hanke AA. Potential value of transfusion protocols in cardiac surgery. *Curr Opin Anaesthesiol* 2013; **26**: 230–43
- 131 Tanaka KA, Kor DJ. Emerging haemostatic agents and patient blood management. *Best Pract Res Clin Anaesthesiol* 2013; **27**: 141–60
- 132 Gombotz H. Patient blood management: a patient-orientated approach to blood replacement with the goal of reducing anemia, blood loss and the need for blood transfusion in elective surgery. *Transfus Med Hemother* 2012; **39**: 67–72
- 133 Shander A, Van Aken H, Colomina MJ, et al. Patient blood management in Europe. *Br J Anaesth* 2012; **109**: 55–68
- 134 Holcomb JB, Del Junco DJ, Fox EE, et al. The Prospective, Observational, Multicenter, Major Trauma Transfusion (PROMMTT) study: comparative effectiveness of a time-varying treatment with competing risks. *JAMA Surg* 2013; **148**: 127–36
- 135 Ranucci M. Fibrinogen supplementation in cardiac surgery: where are we now and where are we going? *J Cardiothorac Vasc Anesth* 2013; **27**: 1–4
- 136 Shakur H, Elbourne D, Gulmezoglu M, et al. The WOMAN Trial (World Maternal Antifibrinolytic Trial): tranexamic acid for the treatment of postpartum haemorrhage: an international randomised, double blind placebo controlled trial. *Trials* 2010; **11**: 40
- 137 Dewan Y, Komolafe EO, Mejia-Mantilla JH, Perel P, Roberts I, Shakur H. CRASH-3—tranexamic acid for the treatment of significant traumatic brain injury: study protocol for an international randomized, double-blind, placebo-controlled trial. *Trials* 2012; **13**: 87

Handling editor: H. C. Hemmings